1. Clinical & Scientific Overview
Esomeprazole Magnesium Trihydrate (TIP-MED-000070, Reference Code [5.2]) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Proton Pump Inhibitor (S-Isomer of Omeprazole).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.2], p. 60): Nexpro (Torrent), Sompraz (Sun Pharma), Raciper (Sun), Esomac (Cipla), Nexium (AstraZeneca); In FDC with Domperidone: Nexpro-RD, Sompraz-D — Strengths & Dosage Forms: Enteric-Coated Tablets / Capsules: 20 mg, 40 mg; Oral Granules for Suspension: 10 mg; IV Injection: 40 mg
Enteric-Coated Tablets / Capsules: 20 mg, 40 mg; Oral Granules for Suspension: 10 mg; IV Injection: 40 mg
3. Mechanism of Action & Pharmacodynamics
Proton Pump Inhibitor (S-Isomer of Omeprazole) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Proton Pump Inhibitor (S-Isomer of Omeprazole) for Severe erosive reflux oesophagitis; GERD; H. pylori eradication; Zollinger-Ellison syndrome; peptic ulcer disease..
4. Therapeutic Indications & Evidence-Supported Uses
- Severe erosive reflux oesophagitis
- GERD
- pylori eradication
- Zollinger-Ellison syndrome
- peptic ulcer disease
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: 20 mg to 40 mg once daily (or 20–40 mg BD in H. pylori eradication / severe erosive disease). Follow physician prescription.
Administration & Meal Timing: Strictly 30 to 60 minutes BEFORE a meal (usually breakfast). Swallow tablets/capsules whole (certain multi-unit pellet capsules may be opened into plain water for NG tube feeding without chewing the pellets). | Once daily 30 minutes before breakfast.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: No dose adjustment needed; monitor for AIN. Hepatic: In severe hepatic impairment (Child-Pugh C), maximum daily dose must not exceed 20 mg once daily.
Renal: No dose adjustment needed; monitor for AIN. Hepatic: In severe hepatic impairment (Child-Pugh C), maximum daily dose must not exceed 20 mg once daily.
Renal: No dose adjustment needed; monitor for AIN. Hepatic: In severe hepatic impairment (Child-Pugh C), maximum daily dose must not exceed 20 mg once daily.
7. Contraindications, Precautions & High-Risk Warnings
- Same class warnings as pantoprazole (exclude gastric malignancy if alarm symptoms present; long-term risks of hypomagnesaemia, B12/iron malabsorption, bone fractures, C. difficile diarrhoea, and acute interstitial nephritis).
Key Clinical Precautions: Renal: No dose adjustment needed; monitor for AIN. Hepatic: In severe hepatic impairment (Child-Pugh C), maximum daily dose must not exceed 20 mg once daily.
8. Adverse Effects Profile
- Headache, abdominal pain, diarrhoea, flatulence, nausea, dry mouth.
- Acute interstitial nephritis, severe hypomagnesaemia, C. difficile-associated diarrhoea, cutaneous lupus erythematosus, fundic gland polyps (benign, with long-term use).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL INTERACTION: Esomeprazole strongly inhibits CYP2C19! Do NOT co-administer with Clopidogrel (blocks activation of clopidogrel and increases cardiovascular/stent thrombosis events—switch to Pantoprazole or Rabeprazole!)
- Also inhibits CYP2C19 clearance of citalopram, escitalopram, diazepam, phenytoin, and cilostazol (increasing their toxicity)
- Reduces pH-dependent absorption of itraconazole, ketoconazole, iron, and cefpodoxime
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Always screen the patient's cardiovascular prescription before dispensing Esomeprazole (Nexpro / Sompraz / Raciper)—if the patient is taking Clopidogrel (Deplatt / Clopitab / Plavix), contact the physician to substitute Pantoprazole or Rabeprazole.
- Meal & Clock Timing Instruction: Strictly 30 to 60 minutes BEFORE a meal (usually breakfast). Swallow tablets/capsules whole (certain multi-unit pellet capsules may be opened into plain water for NG tube feeding without chewing the pellets). (Once daily 30 minutes before breakfast.)
- Missed Dose Protocol: Take 30 minutes before the next meal on the same day; skip if close to next morning's dose.
- Geriatric Dispensing Pearl: Higher plasma bioavailability and slower clearance in the elderly; avoid combining with escitalopram or diazepam as esomeprazole inhibits their CYP2C19 metabolism, increasing sedation and QT/fall risks.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Enteric-Coated Tablets / Capsules: 20 mg, 40 mg; Oral Granules for Suspension: 10 mg; IV Injection: 40 mg
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.2] (p. 60)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.6] Domperidone — Peripheral Dopamine D2-Receptor Antagonist; Gastroprokinetic & An
- [5.7] Ondansetron — Selective Serotonin 5-HT3 Receptor Antagonist; Central & Peripher
- [5.8] Lactulose — Synthetic Non-Absorbable Disaccharide (Galactose-Fructose); Osmot
- [5.9] Bisacodyl — Diphenylmethane Stimulant Laxative (Colonic Myenteric Plexus Stim
